Estimating infectiousness throughout SARS-CoV-2 infection course

  • Terry C. Jones
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Guido Biele
    Norwegian Institute of Public Health, 0473 Oslo, Norway.
  • Barbara Mühlemann
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Talitha Veith
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Julia Schneider
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Jörn Beheim-Schwarzbach
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Tobias Bleicker
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Julia Tesch
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Marie Luisa Schmidt
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Leif Erik Sander
    Department of Infectious Diseases and Respiratory Medicine, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Florian Kurth
    Department of Infectious Diseases and Respiratory Medicine, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Peter Menzel
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Rolf Schwarzer
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Marta Zuchowski
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Jörg Hofmann
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Andi Krumbholz
    Institute for Infection Medicine, Christian-Albrechts-Universität zu Kiel and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
  • Angela Stein
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Anke Edelmann
    Labor Berlin–Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany.
  • Victor Max Corman
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Christian Drosten
    Institute of Virology, Charité­–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.

抄録

<jats:title>Correlates of infectiousness</jats:title> <jats:p> The role that individuals with asymptomatic or mildly symptomatic severe acute respiratory syndrome coronavirus 2 have in transmission of the virus is not well understood. Jones <jats:italic>et al.</jats:italic> investigated viral load in patients, comparing those showing few, if any, symptoms with hospitalized cases. Approximately 400,000 individuals, mostly from Berlin, were tested from February 2020 to March 2021 and about 6% tested positive. Of the 25,381 positive subjects, about 8% showed very high viral loads. People became infectious within 2 days of infection, and in hospitalized individuals, about 4 days elapsed from the start of virus shedding to the time of peak viral load, which occurred 1 to 3 days before the onset of symptoms. Overall, viral load was highly variable, but was about 10-fold higher in persons infected with the B.1.1.7 variant. Children had slightly lower viral loads than adults, although this difference may not be clinically significant. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , abi5273, this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="in-this-issue" xlink:href="10.1126/science.abi5273">eabi5273</jats:related-article> </jats:p>

収録刊行物

  • Science

    Science 373 (6551), eabi5273-, 2021-07-09

    American Association for the Advancement of Science (AAAS)

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ